Recent Scares Could Impede Chinese Generic Exports To U.S.
This article was originally published in PharmAsia News
In light of the recent scare involving Chinese-produced heparin and other safety issues, the budding generics drug industry in China could face a tough sell in the United States. The head of the American drug standards-setting organization, U.S. Pharmacopeia, said the recent product-safety incidents should be of concern to U.S. regulators. But he and another pharmaceutical market expert noted China has the people with skills and drive to comply with good manufacturing practices, enough so to make them a dominant generics marketer to the United States. (Click here for more
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.